By reviewing medical studies and expert opinions, we will try to provide clear and accurate answers
Tirzepatide (Mounjaro, Zepbound) is a once-weekly injectable medication that combines GIP and GLP-1 receptor agonist activity for type 2 diabetes and chronic weight management
There was a tendency towards higher changes in BMI, weight and HbA1c in the patients using an insulin pump
A 2024 retrospective cohort analysis published in Diabetes, Obesity and Metabolism (N=312 patients who switched from semaglutide to tirzepatide at a single academic center) found that switchers lost an additional mean of 6.3% of body weight over 6 months after the switch, with 68% reporting either stable or improved GI tolerability [12]
Caffeine from all sources: 110 mg per can
Reduced Effectiveness: In some cases, the total amount of medication absorbed might also be reduced, potentially leading to a decrease in its intended effect